Categories
Corporate

Adani to split Jaypee assets post-takeover

The National Company Law Tribunal (NCLT) has approved Adani Enterprises Ltd’s resolution plan to acquire Jaiprakash Associates Ltd (JAL), the flagship of the Jaypee Group, under India’s Insolvency and Bankruptcy Code (IBC). This marks a key step in completing one of the largest insolvency acquisitions in the country.

The approved plan, valued at around ₹14,535 crore, received strong support from the Committee of Creditors (CoC) because it offered faster payouts and a practical settlement approach, even though some rival bids, including from Vedanta Ltd, were higher in nominal terms. With the CoC backing, the NCLT granted its sanction, paving the way for Adani to take control.

JAL operates across multiple sectors, including cement, real estate, power, engineering and construction, hospitality, and infrastructure. The Adani Group is now preparing a strategic restructuring of these businesses, which could involve segmenting operations and aligning them with Adani’s specialized entities. This approach is aimed at improving efficiency, maximizing synergies, and enhancing asset utilization.

Despite the approval, the process faces legal scrutiny. Vedanta has appealed to the National Company Law Appellate Tribunal (NCLAT), challenging the NCLT’s decision and the selection of Adani’s plan. The outcome of this appeal may affect the timeline of the asset restructuring.

The acquisition of Jaiprakash Associates, a major infrastructure company burdened with debt, represents a significant expansion of the Adani Group’s presence in India’s industrial and construction sectors.

Also Read: Global energy supply at risk, IEA issues stark warning

Categories
Corporate

NCLT clears ₹8,000-crore SeQuent–Viyash merger

The National Company Law Tribunal (NCLT) has approved the merger of SeQuent Scientific with Viyash Life Sciences in a deal valued at around ₹8,000 crore. The move brings together SeQuent’s animal-health business and Viyash’s pharmaceutical manufacturing capabilities under one larger platform.

As part of the merger, Viyash shareholders will receive 56 SeQuent shares for every 100 shares they hold. Viyash founder Hari Babu Bodepudi is expected to lead the combined entity as CEO once the integration is complete.

The merged company will have a wider global presence, operating across more than 150 countries. It will also benefit from a bigger research and development base and a significantly larger number of US FDA-approved manufacturing facilities.

The consolidation is aimed at improving profitability, strengthening the balance sheet, and unlocking cost efficiencies through shared procurement, operations and scaled-up production. The companies expect the integration to accelerate growth in both animal-health and human-health segments.

Also Read: NHAI opens public investment route for national highways